New combo tackles kidney cancer that came back after immunotherapy
NCT ID NCT07460206
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining two drugs, pembrolizumab and lenvatinib, can help people with advanced kidney cancer (clear cell type) whose cancer returned after prior immunotherapy. About 108 adults will receive the combination to see if it shrinks tumors or delays cancer growth. The goal is to find a better treatment option for this specific group of patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill that starves tumors of oxygen help fight advanced cancer?
- Cell therapy combo aims to boost kidney cancer treatment
- New drug duo aims to shrink advanced kidney tumors
- New scan aims to spot hidden kidney cancers without surgery
- Personalized combo therapy aims to overcome drug resistance in kidney cancer
- Gene test may guide kidney cancer therapy choice